Metabolism of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial

@article{Schofield1999MetabolismON,
  title={Metabolism of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial},
  author={Philip C. Schofield and Iain G. G. Robertson and James W. Paxton and Michael R. McCrystal and Barrie D. Evans and Philip Kestell and B. C. Baguley},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1999},
  volume={44},
  pages={51-58}
}
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA) is an experimental antitumour agent that has just completed phase I clinical trials in New Zealand and the United Kingdom. Urine (0–72 h) was analysed from 20 patients receiving DACA infused over 3 h (dose range 60–1000 mg/m2, the latter being the highest dose achieved in the trial). Aliquots were analysed for DACA and its metabolites by high-performance liquid chromatography (HPLC). Over 72 h, 44 ± 5% (range 20–60%) of the dose was… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS